Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.

Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, Tangye SG, Gaspar HB, Lankester AC, Moretta A, Rickinson AB.

Blood. 2010 Oct 28;116(17):3249-57. doi: 10.1182/blood-2009-09-238832. Epub 2010 Jul 19.

2.

Infectious mononucleosis.

Luzuriaga K, Sullivan JL.

N Engl J Med. 2010 May 27;362(21):1993-2000. doi: 10.1056/NEJMcp1001116. Review. No abstract available. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.

PMID:
20505178
3.

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Gulley ML, Tang W.

Clin Microbiol Rev. 2010 Apr;23(2):350-66. doi: 10.1128/CMR.00006-09. Review.

4.

The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC.

J Virol. 2010 May;84(9):4534-42. doi: 10.1128/JVI.02487-09. Epub 2010 Feb 24.

5.

Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE.

Arthritis Rheum. 2010 Jun;62(6):1693-701. doi: 10.1002/art.27408.

6.

Infectious mononucleosis: recognizing the condition, 'reactivating' the patient.

Eichner ER.

Phys Sportsmed. 1996 Apr;24(4):49-54. doi: 10.3810/psm.1996.04.1306.

PMID:
20086982
7.

Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8.

Chesnokova LS, Nishimura SL, Hutt-Fletcher LM.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20464-9. doi: 10.1073/pnas.0907508106. Epub 2009 Nov 17. Erratum in: Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3275.

8.

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM.

Transplantation. 2009 Oct 27;88(8):1025-9. doi: 10.1097/TP.0b013e3181b9d918.

PMID:
19855249
9.

Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.

Hoshino Y, Katano H, Zou P, Hohman P, Marques A, Tyring SK, Follmann D, Cohen JI.

J Virol. 2009 Nov;83(22):11857-61. doi: 10.1128/JVI.01005-09. Epub 2009 Sep 9.

10.

Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3.

Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K.

J Exp Med. 2009 Sep 28;206(10):2091-9. doi: 10.1084/jem.20081761. Epub 2009 Aug 31.

11.

Evidence-based approach for interpretation of Epstein-Barr virus serological patterns.

Klutts JS, Ford BA, Perez NR, Gronowski AM.

J Clin Microbiol. 2009 Oct;47(10):3204-10. doi: 10.1128/JCM.00164-09. Epub 2009 Aug 5.

12.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Styczynski J, Einsele H, Gil L, Ljungman P.

Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Review.

PMID:
19558376
13.

Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease.

Lee KS, Groshong SD, Cool CD, Kleinschmidt-DeMasters BK, van Dyk LF.

Cancer Res. 2009 Jul 1;69(13):5481-9. doi: 10.1158/0008-5472.CAN-09-0291. Epub 2009 Jun 16.

14.

EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells.

Xiao J, Palefsky JM, Herrera R, Berline J, Tugizov SM.

Virology. 2009 Jun 5;388(2):335-43. doi: 10.1016/j.virol.2009.03.030. Epub 2009 Apr 24.

15.

Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.

Wingate PJ, McAulay KA, Anthony IC, Crawford DH.

J Med Virol. 2009 May;81(5):870-7. doi: 10.1002/jmv.21445.

PMID:
19319950
16.

Antiviral immune responses: triggers of or triggered by autoimmunity?

Münz C, Lünemann JD, Getts MT, Miller SD.

Nat Rev Immunol. 2009 Apr;9(4):246-58. doi: 10.1038/nri2527. Review.

17.

Interlaboratory comparison of epstein-barr virus viral load assays.

Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG; American Society of Transplantation Infectious Diseases Community of Practice.

Am J Transplant. 2009 Feb;9(2):269-79. doi: 10.1111/j.1600-6143.2008.02514.x.

18.

Interleukin-10: new perspectives on an old cytokine.

Mosser DM, Zhang X.

Immunol Rev. 2008 Dec;226:205-18. doi: 10.1111/j.1600-065X.2008.00706.x. Review.

19.

The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway.

Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV.

J Immunol. 2009 Jan 15;182(2):851-9.

20.

Optimal treatment for chronic active Epstein-Barr virus disease.

Cohen JI.

Pediatr Transplant. 2009 Jun;13(4):393-6. doi: 10.1111/j.1399-3046.2008.01095.x. No abstract available.

Supplemental Content

Support Center